NEWTON, Mass.--(BUSINESS WIRE)--Lumicell, Inc., a privately held company focused on innovative fluorescence-guided imaging technologies for cancer surgery, today announced that clinical data from a ...

NEWTON, Mass.--(BUSINESS WIRE)--Lumicell, Inc., a privately held company focused on innovative fluorescence-guided imaging technologies for cancer surgery, today announced the U.S. Food and Drug ...

Permanent HCPCS code granted following U.S. FDA approval of LUMISIGHT™ (pegulicianine) and Lumicell™ Direct Visualization System (DVS), together referred to as LumiSystem™, with commercial ...

NEWTON, Mass., Jan. 27, 2025 /PRNewswire/ -- Lumicell, Inc., a leader in developing innovative fluorescence-guided imaging technologies for cancer detection, today announced the U.S. commercial ...

Permanent HCPCS code granted following U.S. FDA approval of LUMISIGHT™ (pegulicianine) and Lumicell™ Direct Visualization System (DVS), together referred to as LumiSystem™, with commercial ...

Lumicell Inc. sees a brighter future now that it has secured U.S. FDA approval for both its new drug application for Lumisight (pegulicianine) optical imaging agent and premarket approval for the ...

Lumicell Inc. sees a brighter future now that it has secured U.S. FDA approval for both its new drug application for Lumisight (pegulicianine) optical imaging agent and premarket approval for the ...

As many as 40% of lumpectomies leave positive margins that necessitate a second surgery, but a novel fluorescent imaging agent used along with a direct visualization system may improve complete ...